These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20697821)

  • 1. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
    Lorusso D; Ratti M; Ditto A; Raspagliesi F
    Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laparoscopic versus open surgery for endometrial cancer: a minimum 3-year follow-up study.
    Ghezzi F; Cromi A; Uccella S; Siesto G; Giudici S; Serati M; Franchi M
    Ann Surg Oncol; 2010 Jan; 17(1):271-8. PubMed ID: 19826876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
    Kommoss S; Rochon J; Harter P; Heitz F; Grabowski JP; Ewald-Riegler N; Haberstroh M; Neunhoeffer T; Barinoff J; Gomez R; Traut A; du Bois A
    Ann Surg Oncol; 2010 Jan; 17(1):279-86. PubMed ID: 19898901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
    Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R
    Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
    Zang RY; Harter P; Chi DS; Sehouli J; Jiang R; Tropé CG; Ayhan A; Cormio G; Xing Y; Wollschlaeger KM; Braicu EI; Rabbitt CA; Oksefjell H; Tian WJ; Fotopoulou C; Pfisterer J; du Bois A; Berek JS
    Br J Cancer; 2011 Sep; 105(7):890-6. PubMed ID: 21878937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative morbidity and mortality in octogenarians with ovarian cancer.
    Walters CL; Schneider KE; Whitworth JM; Fauci JM; Smith HJ; Barnes MN; Straughn JM
    Int J Gynecol Cancer; 2013 Jul; 23(6):1006-9. PubMed ID: 23714708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
    Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.
    Papadia A; Bellati F; Ditto A; Bogani G; Gasparri ML; Di Donato V; Martinelli F; Lorusso D; Benedetti-Panici P; Raspagliesi F
    Ann Surg Oncol; 2015 Dec; 22(13):4204-10. PubMed ID: 25777095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
    BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402).
    Hirakawa T; Minaguchi T; Itani Y; Kasamatsu Y; Murase S; Sakurada S; Nagano H; Takehara K; Tsuruta T; Arakawa A; Kawano K; Tsubamoto H; Ushiwaka T; Mori T; Iwai K; Saito M; Morisawa H; Saito F; Yoshida K; Kaneuchi M; Sato H; Ito K; Nasu K
    World J Surg Oncol; 2017 Jul; 15(1):132. PubMed ID: 28716033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.